Most Popular
-
1
Korea’s homegrown nanosatellite successfully launches into space
-
2
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
3
Nicaragua shuts down Seoul embassy
-
4
Hybe's multilabel system tested amid conflict with Ador
-
5
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
SNU profs to suspend treatment for one day
-
7
SK hynix pledges W20tr to ramp up DRAM production at home
-
8
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
9
Over-50s, men, single-person households take up majority of those filing for bankruptcy
-
10
Pianist Cho Seong-Jin named Berlin Philharmonic's artist-in-residence
Celltrion's Truxima has 30% market share in Britain
By Catherine ChungPublished : Aug. 1, 2017 - 14:26
An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Tuesday that its biosimilar drug Truxima accounts for 30 percent of the Britain market.
Truxima, a reference to Roche's Mabthera, also known as Rituxan, has become a presence in the European country since its launch in April, Celltrion Healthcare said.
Truxima, a reference to Roche's Mabthera, also known as Rituxan, has become a presence in the European country since its launch in April, Celltrion Healthcare said.
In February, the European Medicines Agency accepted Celltrion's application to sell the antibody biosimilar which is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin's lymphoma, a type of leukemia.
The drug is sold in Britain at a 30 and 40 percent discount to the current list price of Rituxan, the company said.
Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire. (Yonhap)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/25/20240425050656_0.jpg&u=)
